Therapy Detail

Therapy Name ONC201
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ONC201 TIC-10|TIC10 Akt Inhibitor (Pan) 17 ERK Inhibitor (pan) 13 ONC201 (TIC-10) binds to the G-protein coupled receptor, DRD2, leading to inactivation of AKT and ERK, which relocates Foxo3a to the nucleus and then leads to tumor cell apoptosis mediated by (TNF)-related apoptosis-inducing ligand (TRAIL) signaling (PMID: 23390247).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown prostate adenocarcinoma not applicable ONC201 Clinical Study Actionable In a clinical case study, a prostate adenocarcinoma patient demonstrated extended stable disease for 27 weeks when treated with ONC201 (TIC-10) (PMID: 28331050). 28331050
Unknown unknown mantle cell lymphoma not applicable ONC201 Preclinical - Patient cell culture Actionable In a preclinical study, ONC201 induced apoptosis and decreased viability of mantle cell lymphoma (MCL) cell lines in culture and demonstrated cytotoxicity in primary MCL samples in culture (PMID: 26884599). 26884599 detail...
Unknown unknown Advanced Solid Tumor not applicable ONC201 Phase I Actionable In a Phase I trial, ONC201 treatment resulted in stable disease in 80% (8/10) of patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 2514)). detail...
Unknown unknown Advanced Solid Tumor not applicable ONC201 Preclinical - Cell line xenograft Actionable In a preclinical study, ONC-201 (TIC-10) induced apoptosis and tumor regression in a variety of cell line xenograft models, including colon, breast, and brain cancer (PMID: 23390247). 23390247
Unknown unknown acute myeloid leukemia not applicable ONC201 Preclinical - Pdx & cell culture Actionable In a preclinical study, ONC201 treatment induced ATF4 expression and apoptosis in acute myeloid leukemia (AML) cell lines in culture, independent of Tp53 status, and was toxic to AML primary samples in culture, resulting in decreased engraftment in xenograft models (PMID: 26884599). 26884599
AKT1 amp Advanced Solid Tumor predicted - sensitive ONC201 Preclinical - Cell line xenograft Actionable In a preclinical study, ONC201 (TIC-10) inhibited Akt activation and induced apoptosis and tumor regression in a variety of cell line xenograft models (PMID: 23390247). 23390247
Unknown unknown multiple myeloma not applicable ONC201 Preclinical - Cell culture Actionable In a preclinical study, a Velcade (bortezomib)-resistant multiple myeloma cell line demonstrated sensitivity to ONC201 in culture (PMID: 26884599). 26884599
Unknown unknown breast cancer not applicable ONC201 Preclinical - Cell line xenograft Actionable In a preclinical study, ONC201 inhibited viability of several breast cancer cell lines in culture (including triple-negative breast cancer (TNBC) and non-TNBC cell lines), with some cell lines demonstrating increased apoptosis, and inhibited tumor growth in TNBC cell line xenograft models (PMID: 28424227). 28424227
Unknown unknown triple-receptor negative breast cancer not applicable ONC201 Preclinical - Cell line xenograft Actionable In a preclinical study, ONC201 inhibited viability of several triple-negative breast cancer (TNBC) cell lines in culture, demonstrating variable pro-apototic and anti-proliferative activity, and inhibited tumor growth in TNBC cell line xenograft models (PMID: 28424227). 28424227
Unknown unknown endometrial cancer not applicable ONC201 Clinical Study Actionable In a clinical case study, a patient with endometrial cancer demonstrated stable disease for 42 weeks and continued regression of metastatic lesions in the lung when treated with ONC201 (TIC-10) (PMID: 28331050). 28331050
Unknown unknown endometrial clear cell adenocarcinoma not applicable ONC201 Clinical Study Actionable In a clinical case study, a patient with clear cell endometrial cancer treated with ONC201 (TIC-10) demonstrated some reduction in lesion size (>30%), but also developed new lesions (PMID: 28331050). 28331050
Unknown unknown prostate cancer not applicable ONC201 Clinical Study Actionable In a clinical case study, a prostate cancer patient demonstrated tumor regression in the primary tumor and metastatic lesions when treated with ONC201 (TIC-10) (PMID: 28331050). 28331050
Clinical Trial Phase Therapies Title Recruitment Status
NCT03099499 Phase II ONC201 Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer Recruiting
NCT03485729 Phase II ONC201 ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer Recruiting
NCT02525692 Phase II ONC201 Oral ONC201 in Adult Recurrent Glioblastoma Recruiting
NCT03034200 Phase II ONC201 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting
NCT02420795 Phase Ib/II ONC201 Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Recruiting
NCT02392572 Phase Ib/II ONC201 ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS) Recruiting
NCT03295396 Phase II ONC201 ONC201 in Adults With Recurrent High-grade Glioma Recruiting
NCT02324621 Phase I ONC201 Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors Recruiting
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn
NCT03733119 Phase II ONC201 ONC201 With and Without Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer Suspended
NCT03416530 Phase I ONC201 ONC201 in Pediatric H3 K27M Gliomas Recruiting
NCT02863991 Phase II ONC201 Oral ONC201 in Relapsed/Refractory Multiple Myeloma Recruiting
NCT02250781 Phase I ONC201 Akt/ERK Inhibitor ONC201 in Treating Patients With Advanced Solid Tumors Suspended
NCT03394027 Phase II ONC201 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Recruiting
NCT03134131 Expanded access ONC201 Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma Available